Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism TSLP inhibitors(Thymic stromal lymphopoietin inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 2 | Australia | 15 Mar 2024 | |
| Moderate Atopic Dermatitis | Phase 2 | New Zealand | 15 Mar 2024 | |
| Severe Atopic Dermatitis | Phase 2 | Australia | 15 Mar 2024 | |
| Severe Atopic Dermatitis | Phase 2 | New Zealand | 15 Mar 2024 |






